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Cediranib or placebo in combination with cisplatin and 
gemcitabine chemotherapy for patients with advanced 
biliary tract cancer (ABC-03): a randomised phase 2 trial
Juan W Valle, Harpreet Wasan, Andre Lopes, Alison C Backen, Daniel H Palmer, Karen Morris, Marian Duggan, David Cunningham, 
D Alan Anthoney, Pippa Corrie, Srinivasan Madhusudan, Anthony Maraveyas, Paul J Ross, Justin S Waters, Will P Steward, Charlotte Rees, 
Sandy Beare, Caroline Dive, John A Bridgewater
Summary
Background Cisplatin and gemcitabine is the standard ﬁ rst-line chemotherapy regimen for patients with advanced 
biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed to assess the 
eﬀ ect of the addition of cediranib (an oral inhibitor of VEGF receptor 1, 2, and 3) to cisplatin and gemcitabine on 
progression-free survival.
Methods In this multicentre, placebo-controlled, randomised phase 2 study, we recruited patients aged 18 years or 
older with histologically conﬁ rmed or cytologically conﬁ rmed advanced biliary tract cancer from hepatobiliary 
oncology referral centres in the UK. Patients were eligible if they had an ECOG performance status of 0–1 and an 
estimated life expectancy of longer than 3 months. Patients were given ﬁ rst-line cisplatin and gemcitabine 
chemotherapy (25 mg/m² cisplatin and 1000 mg/m² gemcitabine [on days 1 and 8 every 21 days, for up to eight 
cycles]) with either 20 mg oral cediranib or placebo once a day until disease progression. We randomly assigned 
patients (1:1) with a minimisation algorithm, incorporating the stratiﬁ cation factors: extent of disease, primary disease 
site, previous treatment, ECOG performance status, and centre. The primary endpoint was progression-free survival 
in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00939848, and was 
closed on Sept 30, 2014; results of the ﬁ nal analysis for the primary endpoint are presented.
Findings Between April 5, 2011, and Sept 28, 2012, we enrolled 124 patients (62 in each group). With a median follow-
up of 12·2 months (IQR 7·3–18·5), median progression-free survival was 8·0 months (95% CI 6·5–9·3) in the 
cediranib group and 7·4 months (5·7–8·5) in the placebo group (HR 0·93, 80% CI 0·74–1·19, 95% CI 0·65–1·35; p=0·72). 
Patients who received cediranib had more grade 3–4 toxic eﬀ ects than did patients who received placebo: hypertension 
(23 [37%] vs 13 [21%]; p=0·05), diarrhoea (eight [13%] vs two [3%]; p=0·05); platelet count decreased (ten [16%] vs four 
[6%]; p=0·09), white blood cell decreased (15 [24%] vs seven [11%]; p=0·06) and fatigue (16 [24%] vs seven [11%]; 
p=0·04).
Interpretation Cediranib did not improve the progression-free survival of patients with advanced biliary tract cancer 
in combination with cisplatin and gemcitabine, which remains the standard of care. Although patients in the 
cediranib group had more adverse events, we recorded no unexpected toxic eﬀ ects. The role of VEGF inhibition in 
addition to chemotherapy for patients with advanced biliary tract cancer remains investigational.
Funding Cancer Research UK and AstraZeneca Pharmaceuticals.
Copyright © Valle et al. Open Access article distributed under the terms of CC BY.
Introduction
Inoperable or metastatic cholangiocarcinomas, gall-
bladder, and ampullary cancers are collectively termed 
advanced biliary tract cancers. Although these diseases 
are deemed to be low incidence in most high-income 
countries (<1% of all adult cancers, with roughly 
1500 cases per year in the UK1 and 9000 cases per year 
in the USA2), global hotspots exist with much higher 
incidence. Importantly, both incidence and mortality 
are increasing largely due to a global rise in intrahepatic 
cholangio carcinoma.3
Most patients present with locally advanced (non-
resectable) or metastatic disease and, even when surgery 
is feasible, recurrence is frequent. The median survival 
with best supportive care in randomised studies is 
between 2·5 and 4·5 months.4,5 The National Cancer 
Research Institute (UK) Advanced Biliary tract Cancer 
(ABC)-02 randomised phase 3 study,6 established cisplatin 
and gemcitabine as the reference ﬁ rst-line chemotherapy 
regimen for advanced biliary tract cancer with a median 
overall survival of 11·7 months, a ﬁ nding that was 
replicated in a randomised phase 2 Japanese study.7 
However, with only half of patients with advanced disease 
surviving a year, improved treatment options are needed.
VEGF, one of the main growth factors regulating 
angiogenesis, is overexpressed in 40–75% of biliary tract 
Lancet Oncol 2015; 16: 967–78
Published Online
July 13, 2015
http://dx.doi.org/10.1016/
S1470-2045(15)00139-4
See Comment page 882
Institute of Cancer Studies, 
University of Manchester, 
Manchester, UK 
(Prof J W Valle MD, 
A C Backen PhD); The Christie 
NHS Foundation Trust, 
Manchester, UK (Prof J W Valle); 
Imperial College Healthcare 
NHS Trust, London, UK 
(H Wasan MD); Cancer Research 
UK and UCL Cancer Clinical 
Trials Centre, London, UK 
(A Lopes MSc, M Duggan MSc, 
S Beare PhD); University of 
Liverpool and Clatterbridge 
Cancer Centre, Liverpool, UK 
(Prof D H Palmer PhD); The 
Royal Marsden NHS 
Foundation Trust, London, UK 
(Prof D Cunningham MD); 
St James University Hospital, 
The Leeds Teaching Hospital 
Trust, Beckett Street, Leeds, 
UK (D A Anthoney MD); 
Cambridge University 
Hospitals NHS Foundation 
Trust, Cambridge, UK 
(P Corrie MD); Nottingham City 
Hospital, Nottingham 
University Hospitals NHS 
Trust, Nottingham, UK 
(S Madhusudan MD); Hull York 
Medical School, Castle Hill 
Hospital, Hull, UK 
(Prof A Maraveyas MD); Guy’s 
Hospital, Guy’s and St Thomas’ 
NHS Foundation Trust, 
London, UK (P J Ross MD); Kent 
Oncology Centre, Maidstone 
Hospital, Kent, UK 
(J S Waters PhD); Leicester Royal 
Inﬁ rmary, University Hospitals 
of Leicester NHS Trust, 
Leicester, UK 
(Prof W P Steward PhD); 
Southampton University 
Hospitals NHS Foundation 
Trust, Southampton, UK 
(C Rees MD); Cancer Research 
UK Manchester Institute, 
Articles
968 www.thelancet.com/oncology   Vol 16   August 2015
University of Manchester, 
Manchester, UK (K Morris PhD, 
Prof C Dive PhD); and UCL 
Cancer Institute, London, UK 
(J A Bridgewater MD)
Correspondence to:
Prof Juan W Valle, Institute of 
Cancer Sciences, University of 
Manchester and Manchester 
Academic Health Sciences 
Centre/The Christie NHS 
Foundation Trust, 
Manchester, M20 4BX, UK
juan.valle@manchester.ac.uk
cancers,8–10 especially at the invasive edge of the tumour.11 
The receptors for this ligand, VEGFR1 and VEGFR2, are 
also overexpressed in the adjacent endothelial cells.12 
VEGF expression is associated with the presence of 
metastases in intrahepatic cholangiocarcinoma;8 
adverse prognosis in extrahepatic cholangiocarcinoma13 
and increased microvascular density in both cholangio-
carcinoma9 and gallbladder cancer.10 In turn, high 
micro vascular density is an independent adverse 
prognostic factor for disease-free survival after resection 
of extrahepatic cholangiocarcinoma11 and for overall 
survival in lymph-node negative intrahepatic cholangio-
carcinoma14 and gallbladder cancer.10 These results make 
angiogenesis a logical target for treatment of biliary 
tract cancer.
Cediranib is an oral VEGFR1, VEGFR2, and VEGFR3 
tyrosine kinase inhibitor, with additional activity against 
PDGF receptors and c-KIT.15 Although the maximum 
tolerated dose of cediranib was not reached in a phase 1 
study16 in patients with lung cancer, the recommended 
dose was 30 mg once a day in combination with cisplatin 
and gemcitabine (using a diﬀ erent schedule to that of the 
ABC-02 study, namely 1250 mg/m² gemcitabine on 
days 1 and 8 and 80 mg/m² cisplatin on day 1 every 
3 weeks). However, based on the totality of the available 
safety, tolerability, eﬃ  cacy, pharmacokinetic, and 
pharmacodynamic data at the time of study setup, the 
manufacturer’s recommended dose of 20 mg cediranib 
once a day for combination with chemotherapy regimens 
was selected for this trial.
In this trial, ABC-03, we aimed to assess the eﬀ ect of 
the addition of cediranib to standard cisplatin and 
gemcitabine chemotherapy on progression-free survival 
in patients with advanced biliary tract cancer.
Methods
Study design and participants
In this multicentre, randomised phase 2, double-blind, 
placebo-controlled, investigator-initiated study, we 
recruited patients aged 18 years or older with a histo-
pathological or cytological diagnosis of non-resectable, 
recurrent, or metastatic biliary tract carcinoma (intra-
hepatic or extrahepatic cholangiocarcinoma), gallbladder, 
or ampullary carcinoma from hepatobiliary oncology 
referral centres in the UK. Patients were eligible if they 
had an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–1 and an estimated life 
expectancy of longer than 3 months.
Patients were required to have adequate haematological 
function (haemoglobin ≥10 g/dL; white blood cell count 
≥3·0 × 10⁹ cells per L; absolute neutrophil count ≥1·5 × 10⁹ 
cells per L and platelet count ≥100 × 10⁹ per L), hepatic 
function (total bilirubin ≤1·5 times the upper limit of 
normal except for patients with known documented cases 
of Gilbert’s syndrome; alanine aminotransferase or 
aspartate aminotransferase ≤2·5 times the upper limit of 
normal [if liver metastases were present, alanine 
aminotransferase or aspartate aminotransferase had to be 
less than ﬁ ve times the upper limit of normal] and alkaline 
phosphatase less than or equal to ﬁ ve times the upper limit 
of normal), and renal function (serum urea <1·5 times the 
upper limit of normal, serum creatinine <1·5 times the 
upper limit of normal, and calculated glomerular ﬁ ltration 
rate ≥45 mL/min using a validated creatinine clearance 
calculation such as Cockroft-Gault or Wright formula [if the 
calculated glomerular ﬁ ltration rate was below 45 mL/min, 
an isotopic method was done to conﬁ rm the glomerular 
ﬁ ltration rate was ≥45 mL/min]). Additionally, patients 
could not have evidence of active uncontrolled infection 
Research in context
Evidence before this study
Chemotherapy with cisplatin and gemcitabine is the reference 
chemotherapy regimen for patients with advanced biliary tract 
cancer based on the largest randomised trial in this population 
(ABC-02). Up to now, no randomised trial has shown 
superiority of any systemic therapy over this combination. 
Targeting angiogenesis, one of the hallmarks of cancer and a 
known predictor of adverse outcome in advanced biliary tract 
cancer, is a logical step and has proven to be eﬀ ective in a 
number of tumour types; however, no randomised studies have 
been done of this approach in advanced biliary tract cancer 
building on the cisplatin and gemcitabine regimen.
Added value of this study
This study assessed the eﬀ ect of adding cediranib (an oral 
VEGFR-1, VEGFR-2 and VEGFR-3 receptor tyrosine kinase 
inhibitor, with additional activity against PDGF receptors and 
c-KIT) to cisplatin and gemcitabine chemotherapy in a 
double-bind, placebo-controlled manner. The study did not 
meet its primary endpoint (improvement in progression-free 
survival); however, we recorded signals that would support 
further anti-angiogenesis approaches. Additionally, we showed 
that elevated baseline levels of the tumour markers CEA and 
CA125 (in addition to CA19-9) and total cytokeratin 18 and 
VEGFR2 are prognostic in advanced biliary tract cancer. This is 
the ﬁ rst study to show that the presence of circulating tumour 
cells confers an adverse prognosis, and oﬀ ers an opportunity to 
interrogate these in future studies. Finally, baseline PDGFbb 
concentrations might predict for cediranib activity.
Implications of all the available evidence
Cisplatin and gemcitabine remains the reference regimen for 
patients with advanced biliary tract cancer; there is no evidence 
that cediranib improves progression-free survival. The eﬀ ect of 
a better-tolerated anti-angiogenic in combination with 
cisplatin and gemcitabine, with consideration of our 
exploratory ﬁ ndings with respect to circulating biomarkers, 
warrants further investigation. 
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(patients on long-term antibiotics were eligible provided 
signs of active infection had resolved) and women of 
childbearing potential were required to have a negative 
pregnancy test before study entry and to be using two 
methods of adequate contraception, which was to be 
continued for 3 months after completion of treatment.
The following previous treatment was allowed 
(provided there had been a full recovery): a non-curative 
operation (ie, R2 resection [with macroscopic residual 
disease] or palliative bypass surgery only); curative 
surgery with evidence of non-resectable disease relapse 
requiring systemic chemotherapy; radiotherapy (with or 
without radio-sensitising low-dose chemotherapy) for 
localised disease provided there had been clear evidence 
of disease progression before inclusion in this study; 
adjuvant chemotherapy provided neither gemcitabine 
nor cisplatin were used and the treatment was completed 
more than 6 months before trial entry; and photodynamic 
treatment provided that there was clear evidence of 
disease progression at the local site or at a new metastatic 
site. Previous systemic chemotherapy for locally 
advanced or metastatic disease was not allowed.
Patients were excluded from the study in the event of 
incomplete recovery (common terminology criteria for 
adverse events [CTCAE] grade >1) from previous anticancer 
treatment; unresolved biliary tree obstruction; continuing 
severe or uncontrolled systemic diseases which, in the 
view of the investigator, made it undesirable for the patient 
to participate in the trial (eg, unstable or uncompensated 
respiratory, cardiac, hepatic, or renal disease); or untreated 
unstable brain or meningeal metastases. Pregnant or 
breastfeeding women; patients with a history of cancer 
likely to interfere with the response assessment (exceptions 
include in-situ carci noma of the cervix treated by cone-
biopsy or resection, non-metastatic basal or squamous cell 
carcinomas of the skin, any early stage [stage I] cancer 
adequately resected for cure >5 years previously); and 
patients in receipt of treatment with an investigational 
drug within 30 days before randomisation were excluded.
Cediranib-directed exclusions included substantial 
haemorrhage (>30 mL bleeding or episode in previous 
3 months) or haemoptysis (>5 mL fresh blood) within 
4 weeks of randomisation; poorly controlled hypertension 
with resting blood pressure higher than 150/100 mm Hg 
in the presence or absence of a stable regimen of anti-
hypertensive treatment, or patients requiring maximum 
doses of calcium channel blockers to stabilise blood 
pressure; proteinuria of greater than +1 on two con-
secutive dipsticks taken no less than 1 week apart, unless 
urinary protein less than 1·5 g in 24 h or protein to 
creatinine ratio less than 1·5; a mean QTc with Bazett’s 
correction longer than 480 ms in screening ECG or history 
of familial long QT syndrome; recent major thoracic or 
abdominal surgery (<14 days) before randomisation, or an 
incompletely healed surgical incision; known hyper-
sensitivity to cediranib or any of its excipients; or a history 
of gastrointestinal impairment that would substantially 
aﬀ ect the absorption of cediranib or placebo. Because of 
the intensity of laboratory processing of blood products, 
we also excluded patients with known risk of transmitting 
HIV, hepatitis B or C via infected blood.
The trial was done according to the principles of the 
International Conference on Harmonisation of Good 
Clinical Practice. It was coordinated by the Cancer 
Research UK and University College London (UCL) 
Cancer Trials Centre and sponsored by UCL. All patients 
provided written informed consent before randomisation.
Randomisation and masking
Patients were randomly assigned (1:1) to receive either 
cediranib or matching placebo in addition to cisplatin 
and gemcitabine chemotherapy. Treatment was assigned 
by computer (undertaken centrally at UCL Cancer Trials 
Centre, UK) with a minimisation algorithm incor-
porating the stratiﬁ cation factors: extent of disease 
(locally advanced vs metastatic), primary disease site 
(gallbladder vs bile duct vs ampulla), previous treatment 
(none vs adjuvant chemotherapy vs other), ECOG per-
formance status (0 vs 1) and randomising site, and includ-
ing a random element.
Supply and allocation of oral drug packs was managed 
by an interactive web-based response system (Cenduit, 
Stirling, UK). The allocated oral treatment was masked to 
the respective patients, treating clinician, local site staﬀ , 
and UCL Cancer Trials Centre staﬀ  until analysis. An 
emergency unmasking procedure was established at 
each study site for patient safety.
Procedures
Once deemed eligible at study screening, all patients 
received 25 mg/m² cisplatin and 1000 mg/m² 
gemcitabine chemotherapy, each on days 1 and 8 of a 
21 day cycle, continued to eight cycles in the absence of 
disease progression. Additionally, patients received either 
20 mg oral cediranib once a day or placebo throughout 
and beyond the completion of chemotherapy in the 
absence of disease progression. Treatment was dis-
continued in the event of disease progression, un-
acceptable adverse events, intercurrent illness preventing 
further treatment, a patient’s decision to withdraw con-
sent, or any alteration in the patient’s condition justifying 
discontinuation in the site investigator’s opinion. In 
these cases, patients remained within the trial for the 
purposes of follow-up and data analysis according to the 
treatment group to which they were allocated.
Disease status was assessed by CT scans (and MRI 
scans, if appropriate) at baseline, and every 3 months 
until disease progression (including patients who 
discontinued treatment for any reason other than disease 
progression). Response was assessed by local investigators 
according to RECIST (version 1.1; no central review was 
done); with reporting radiologists masked to the patients’ 
treatment. Additionally, the tumour markers CA19-9, 
CEA, and CA125 were assessed at baseline, on day 1 of 
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every cycle of chemotherapy, monthly when on cediranib 
or placebo, and then at end of treatment.
Adverse events were graded according to CTCAE 
(version 4.03). To proceed with administration of full 
dose gemcitabine and cisplatin on days 1 and 8 of each 
cycle the following were required: white blood cell count 
of 2 × 10⁹ cells per L or higher, absolute neutrophil count 
of 1 × 10⁹ cells per L or higher, platelets 100 × 10⁹ per L or 
higher, and glomerular ﬁ ltration rate of 45 mL/min or 
higher. If gemcitabine was deferred, the cisplatin was 
also deferred. Day 8 treatment was deferred for toxic 
eﬀ ect by 1 week only. If a second deferral was needed, the 
treatment was omitted and the patient moved on to the 
next treatment cycle.
Only one dose reduction for cediranib, from 20 mg 
once a day to 15 mg once a day (or placebo equivalent, 
maintaining treatment masking), was allowed. Protocol-
speciﬁ c guidance was provided for adverse events of 
interest, particularly diarrhoea, hypertension, fatigue, 
proteinuria, hypothyroidism, and reversible posterior 
leukoencephalopathy syndrome. Dose interruptions 
were used as the ﬁ rst approach to manage adverse events 
related to cediranib; for adverse events of grade 3 or 
more, dosing with cediranib or placebo was interrupted. 
For patients with several low-grade adverse events (eg, 
diarrhoea, weight loss, dehydration, and fatigue) short 
dose interruptions (ie, 2–5 days) of the cediranib or 
placebo tablets were instituted. Treatment was then 
restarted on resolution of the adverse event at the same 
dose. An interruption of up to 14 days for management of 
cediranib or placebo adverse events was allowed. If the 
adverse event promptly resolved with supportive care, 
cediranib or placebo restarted at the same dose along 
with appropriate continuing supportive care. If the 
adverse event was deemed related to cediranib and did 
not resolve to grade 1 or lower with maximum supportive 
care and following a dose delay of up to 14 days, cediranib 
or placebo was restarted at 15 mg once a day. If the 
adverse event failed to resolve, and it was regarded as 
medically appropriate, cediranib or placebo was 
permanently discontinued; if cediranib or placebo could 
not be restarted at either full or reduced dose after 
14 days, it was permanently discontinued. Where 
possible, cediranib or placebo was suspended for 2 weeks 
to allow clearance before any major surgery, if required.
Blood was collected from patients for exploratory 
biomarker studies and processed into EDTA plasma at up 
to 11 timepoints; a ﬁ rst pretreatment baseline sample, a 
second pretreatment baseline sample on day 1 of the ﬁ rst 
cycle then on the ﬁ rst day of cycles 2–8, at the end of 
chemotherapy, and 1 month after the end of chemo therapy. 
We measured circulating markers of angio genesis 
(VEGFA, VEGFC, VEGFR1, VEGFR2, Ang1, Ang2, FGFb, 
HGF, PDGFbb, KGF, PlGF, Tie2, and SDF1b) and 
inﬂ ammation (interleukin 6 and interleukin 8) with a 
validated multiplex ELISA platform (Aushon BioSystems, 
Billerica, MA, USA), according to Good Clinical Practice 
(GCP) standards at the Cancer Research UK Manchester 
Institute (Manchester, UK).17 Con centrations of circulating 
total CK18, released from epithelial cells during death 
(apoptosis and necrosis), were measured with an M65 
ELISA (Peviva, Nacka, Sweden), also previously validated 
and implemented to GCP as described.18
Whole blood (10 mL) was collected in CellSave tubes at 
up to four timepoints (pretreatment baseline sample, on 
day 1 of cycles two and ﬁ ve, and 1 month after the end of 
chemotherapy) for enumeration of circulating tumour 
cells with the CellSearch platform (Janssen Diagnostics, 
South Raritan, NJ, USA) within 4 days of blood draw.19 
Brieﬂ y, after immunomagnetic capture of EpCAM-
positive cells, immunophenotyping using cytokeratin 
(CK), DAPI, and CD45 allowed classiﬁ cation of circulating 
tumour cells as EpCAM+, CK+, DAPI+, and CD45–.
Only results of the baseline circulating biomarker 
values are presented in this report; analysis of cell-free 
DNA, detailed biostatistics of longitudinal samples and 
exploratory analysis by subgroup (in view of the biological 
heterogeneity of biliary tract cancers) is in progress and 
will be published separately.
Outcomes
The primary endpoint was progression-free survival; 
secondary endpoints were overall survival, response by 
RECIST (version 1.1), assessment of adverse events, and 
29 completed eight cycles of cisplatin and 
gemcitabine
33 discontinued cisplatin and gemcitabine
9 disease progression
5 symptomatic deterioration
2 clinician choice
1 patient decision
16 toxic eﬀects
Reason why oral treatment was discontinued:
27 disease progression
24 toxic eﬀects
5 symptomatic deterioration
3 patient decision
1 intercurrent illness
1 delay in taking oral treatment
1 did not start cediranib
29 completed eight cycles of cisplatin and 
gemcitabine
31 discontinued cisplatin and gemcitabine
18 disease progression
4 symptomatic deterioration
2 clinician choice
2 patient decision
5 toxic eﬀects
Reason why oral treatment was discontinued:
34 disease progression
15 toxic eﬀects
4 symptomatic deterioration
2 clinician decision
1 patient decision
1 delay in taking oral treatment
3 had oral treatment unblinded
Allocation 
Follow-up 
Analysis 62 patients analysed 
62 randomly assigned to cediranib
62 received the allocated intervention 
62 randomly assigned to placebo
60 received the allocated intervention
2 did not start cisplatin and gemcitabine 
and allocated intervention (not ﬁt for
treatment) 
3 lost to follow-up 
62 patients analysed 
124 patients assessed for eligibility 
0 lost to follow-up 
Figure 1: Trial proﬁ le
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quality of life. Samples were also taken for exploratory 
biomarker analysis (including archival tumour tissue, 
and blood samples for circulating tumour cells and a 
panel of angiogenesis ELISAs).
Statistical analysis
The trial was designed to directly compare progression-
free survival between the two treatment groups, with 
80% power and a two-sided alpha of 0·2, to detect a 
progression-free survival hazard ratio (HR) of 0·64. 
This required a sample size of 68 per group. The main 
analysis involved estimating the HR, 80% CI, and 
p value. If the HR was less than 1 and the p value was less 
than 0·2, the study would be deemed to have provided 
suﬃ  cient evidence to do a larger trial, after considering 
toxic eﬀ ects, with a high threshold of activity. This was 
based on seeing an improvement in the median 
progression-free survival from 8 months to 12·5 months, 
with recruitment lasting for 18 months and patients 
followed up for 12 months beyond last recruitment; 
requiring 92 progression-free survival events. No formal 
interim analysis was planned or done for this trial. 
During the conduct of the study, the end of recruitment 
became ﬁ xed by date (Sept 30, 2012) rather than by 
accrual following the decision by the manufacturer to 
cease development of cediranib; consequently, the power 
of the study was reduced to 75% and the target sample 
size adjusted accordingly to include at least 116 patients.
We plotted Kaplan-Meier curves for progression-free 
survival and overall survival; treatment eﬀ ect HR (with 
80% and 95% CIs and p values) were obtained from Cox 
proportional hazards regression models. An HR lower 
than 1 favoured the cediranib group. The proportionality 
assumption of the Cox model was tested with Schoenfeld 
residuals. We calculated adjusted and unadjusted HR and 
reported unadjusted HR. The principal analysis included 
all patients by allocated treatment group on an intention-
to-treat basis. Survival endpoints were measured from 
date of randomisation to date of event. For progression-
free survival, symptomatic deterioration was accepted as 
disease progression (patients with a global deterioration of 
Cediranib group 
(n=62)
Placebo group 
(n=62)
Age (years) 68·0 (60·4–73·0) 64·5 (59·7–73·1)
Sex
Female 28 (45%) 34 (55%)
Male 34 (55%) 28 (45%)
Primary tumour site
Cholangiocarcinoma 38 (61%) 39 (63%)
Intrahepatic 14 (23%) 15 (24%)
Extrahepatic 24 (39%) 24 (39%)
Gallbladder 20 (32%) 19 (31%)
Ampulla 4 (6%) 4 (6%)
Histological grade
Well diﬀ erentiated 26 (42%) 27 (44%)
Moderately diﬀ erentiated 20 (32%) 21 (34%)
Poorly diﬀ erentiated 13 (21%) 13 (21%)
Not speciﬁ ed 3 (5%) 1 (2%)
Previous treatment
Adjuvant chemotherapy 2 (3%) 1 (2%)
Other* 23 (37%) 22 (35%)
None 37 (60%) 39 (63%)
ECOG performance status
0 27 (44%) 28 (45%)
1 35 (56%) 34 (55%)
Disease status
Locally advanced 12 (19%) 8 (13%)
Metastatic 50 (81%) 54 (87%)
Liver 36 (58%) 34 (55%)
Peritoneum 19 (31%) 5 (8%)
Omentum 5 (8%) 4 (6%)
Lung 6 (10%) 9 (15%)
CA19-9 (IU/mL)† 298 (38–2258) 53 (10–492)
Data are median (IQR) or n (%). ECOG=Eastern Cooperative Oncology Group. 
*33 patients had surgery only (16 in the cediranib group and 17 in the placebo 
group) and 12 had surgery plus biliary stent insertions (seven in the cediranib 
group and ﬁ ve in the placebo group). †CA19-9 was assessable in 59 patients in 
each group. 
Table 1: Baseline characteristics
Cediranib group (N=62) Placebo group (N=62) p value*
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Haematological adverse events
Anaemia 51 (82%) 8 (13%) 49 (79%) 8 (13%) 0·99
Platelet count decreased 34 (55%) 10 (16%) 28 (45%) 4 (6%) 0·09
White blood cell decreased 28 (45%) 15 (24%) 32 (52%) 7 (11%) 0·06
Neutrophil count decreased 22 (35%) 26 (42%) 20 (32%) 23 (37%) 0·58
 Any haematological adverse event 13 (21%) 49 (79%) 12 (19%) 49 (79%) 0·99
Liver function adverse events
Increased alanine aminotransferase 43 (69%) 7 (11%) 39 (63%) 4 (6%) 0·34
Increased alkaline phosphatase 43 (69%) 4 (6%) 43 (69%) 4 (6%) 0·99
Increased aspartate 
aminotransferase
40 (65%) 3 (5%) 35 (56%) 2 (3%) 0·65
Increased gamma-glutamyl 
transpeptidase
32 (52%) 29 (47%) 23 (37%) 31 (50%) 0·72
Increased blood bilirubin 9 (15%) 3 (5%) 9 (15%) 4 (6%) 0·70
Non-haematological adverse events
Constipation 42 (68%) 0 (0%) 42 (68%) 0 (0%) ··
Anorexia 40 (65%) 3 (5%) 25 (40%) 2 (3%) ··
Nausea 39 (63%) 4 (6%) 42 (68%) 1 (2%) ··
Diarrhoea 37 (60%) 8 (13%) 22 (35%) 2 (3%) 0·05
Fatigue 36 (58%) 16 (26%) 40 (65%) 7 (11%) 0·04
Lethargy 35 (56%) 8 (13%) 35 (56%) 7 (11%) 0·78
Hypoalbuminaemia 31 (50%) 0 (0%) 23 (37%) 0 (0%) ··
Abdominal pain 28 (45%) 4 (6%) 27 (44%) 5 (8%) ··
Hyponatraemia 26 (42%) 10 (16%) 28 (45%) 4 (6%) 0·09
Hypercalcaemia 25 (40%) 2 (3%) 22 (35%) 0 (0%) ··
Vomiting 24 (39%) 6 (10%) 21 (34%) 9 (15%) 0·41
(Table 2 continues on next page)
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health status requiring dis continuation of treatment 
without objective evidence of disease progression at that 
time were classiﬁ ed as having symptomatic deterioration).
Best overall response was summarised as frequencies, 
and the diﬀ erence of proportions test (with 95% CI and 
p value) was used to compare responses and disease 
control between the two groups. Only patients with 
measurable disease at baseline were included in this 
analysis. Duration of response was measured from the 
date the best overall response was documented to the 
date of progression-free survival event.
All treatment-emergent adverse events reported are 
presented and summarised as frequencies; we used 
Pearson’s χ² test of association to formally compare 
grade 3–4 adverse events occurring in at least ten patients. 
We used the Kaplan-Meier method and Cox regression 
model to compare the median time on each treatment.
The associations of biomarkers (ELISA, total CK18 
[M65], circulating tumour cell count, CEA, CA19-9, and 
CA125) with overall survival and progression-free survival 
were assessed with Cox regression models. The biomarkers 
were included in the Cox models as continuous and 
categorical variables. All overall survival and progression-
free survival models were adjusted for treatment group 
and baseline characteristics (age, sex, ECOG performance 
status, primary site, stage, and previous treatment). Overall 
survival and progression-free survival Cox models were 
used to test for interactions between treatment and each 
biomarker (handled as continuous and binary variables). 
Treatment eﬀ ect on overall survival and progression-free 
survival were assessed for lower and higher values of each 
baseline biomarker. Kaplan-Meier curves were used to 
graphically represent the ﬁ ndings. All Cox models were 
assessed for the pro portionality of hazards assumption. No 
correction was made for multiple testing.
All analyses were done in Stata (version 12). This study is 
registered with ClinicalTrials.gov, number NCT00939848.
Role of the funding source
The academic chief investigator (JWV), in conjunction 
with UCL, was responsible for the study design and 
conduct including the collection, management, analysis, 
and interpretation of the data; along with the preparation, 
review, and approval of the presentation and publication 
of the study. Study conduct was overseen by an 
independent trial steering committee. The trial 
management group had access to all the raw data and 
take full responsibility for the integrity of the data and 
accuracy of the data analysis. The chief investigator had 
full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Between April 5, 2011, and Sept 28, 2012, 124 patients were 
recruited from 14 UK sites (tertiary hepatobiliary oncology 
referral centres; appendix). Figure 1 shows the trial proﬁ le. 
Table 1 shows the patient characteristics at baseline. The 
Cediranib group (N=62) Placebo group (N=62) p value*
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
(Continued from previous page)
Hypomagnesaemia 23 (37%) 7 (11%) 18 (29%) 3 (5%) 0·19
Mucositis oral 23 (37%) 2 (3%) 13 (21%) 0 (0%) ··
Hypophosphataemia 23 (37%) 2 (3%) 17 (27%) 2 (3%) ··
Oedema limbs 22 (35%) 0 (0%) 16 (26%) 1 (2%) ··
Pain 22 (35%) 8 (13%) 25 (40%) 4 (6%) 0·22
Dysgeusia 20 (32%) 0 (0%) 19 (31%) 0 (0%) ··
Hypokalaemia 20 (32%) 1 (2%) 18 (29%) 0 (0%) ··
Hypertension 19 (31%) 23 (37%) 17 (27%) 13 (21%) 0·05
Creatinine increased 17 (27%) 0 (0%) 10 (16%) 0 (0%) ··
Peripheral sensory neuropathy 15 (24%) 1 (2%) 16 (26%) 0 (0%) ··
Fever 15 (24%) 3 (5%) 14 (23%) 1 (2%) ··
Dyspnoea 15 (24%) 1 (2%) 16 (26%) 3 (5%) ··
Epistaxis 15 (24%) 2 (3%) 6 (10%) 0 (0%) ··
Dry mouth 14 (23%) 1 (2%) 8 (13%) 0 (0%) ··
Upper respiratory infection 14 (23%) 1 (2%) 5 (8%) 4 (6%) ··
Cough 13 (21%) 0 (0%) 8 (13%) 0 (0%) ··
Dyspepsia 13 (21%) 0 (0%) 7 (11%) 0 (0%) ··
Flu-like symptoms 12 (19%) 0 (0%) 12 (19%) 0 (0%) ··
Back pain 12 (19%) 3 (5%) 10 (16%) 1 (2%) ··
Generalised muscle weakness 12 (19%) 1 (2%) 6 (10%) 0 (0%) ··
Rash maculopapular 12 (19%) 0 (0%) 5 (8%) 1 (2%) ··
Sore throat 11 (18%) 0 (0%) 6 (10%) 0 (0%) ··
Weight loss 11 (18%) 1 (2%) 4 (6%) 0 (0%) ··
Gastro-oesophageal reﬂ ux disease 10 (16%) 0 (0%) 17 (27%) 0 (0%) ··
Insomnia 10 (16%) 1 (2%) 12 (19%) 0 (0%) ··
Alopecia 10 (16%) 0 (0%) 18 (29%) 0 (0%) ··
Urinary tract infection 9 (15%) 0 (0%) 5 (8%) 2 (3%) ··
Pain in extremity 8 (13%) 0 (0%) 5 (8%) 1 (2%) ··
Myalgia 7 (11%) 0 (0%) 11 (18%) 0 (0%) ··
Papulopustular rash 7 (11%) 0 (0%) 3 (5%) 0 (0%) ··
Flatulence 7 (11%) 0 (0%) 6 (10%) 0 (0%) ··
Dizziness 6 (10%) 0 (0%) 8 (13%) 0 (0%) ··
Mucosal infection 6 (10%) 0 (0%) 2 (3%) 0 (0%) ··
Chills 5 (8%) 0 (0%) 2 (3%) 0 (0%) ··
Biliary tract infection 3 (5%) 5 (8%) 0 (0%) 3 (5%) ··
Tinnitus 3 (5%) 1 (2%) 9 (15%) 0 (0%) ··
Hearing impaired 2 (3%) 1 (2%) 7 (11%) 0 (0%) ··
Lung infection 2 (3%) 2 (3%) 9 (15%) 2 (3%) ··
Sepsis 1 (2%) 5 (8%) 1 (2%) 2 (3%) ··
Thromboembolic event 0 (0%) 7 (11%) 1 (2%) 8 (13%) 0·78
Febrile neutropenia 0 (0%) 4 (6%) 0 (0%) 1 (2%) ··
Myocardial Infarction 0 (0%) 1 (2%) 0 (0%) 0 (0%) ··
Non-cardiac chest pain 0 (0%) 2 (3%) 6 (10%) 0 (0%) ··
Hepatobiliary disorder—biliary 
obstruction
0 (0%) 0 (0%) 0 (0%) 4 (6%) ··
Hepatic infection 0 (0%) 0 (0%) 0 (0%) 1 (2%) ··
Data are n (%). *Comparison of incidence of grade 3–4 events in at least ten patients (Pearson’s χ² test). †Five patients 
had a grade 5 adverse event, three in the cediranib group (one myocardial infarction, one cerebrovascular accident, one 
gastric haemorrhage) and two in the placebo group (one cholangitis, one peripheral ischaemia).
Table 2: Treatment-emergent adverse events arising in ≥10% patients, or of special interest, 
irrespective of cause
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median patient age was 65·1 years, 50% of patients were 
men, and most patients (84%) had metastatic disease. 
Most patients had primary tumours arising from the bile 
ducts (62%) followed by gallbladder cancer (31%) and 
ampullary tumours (6%); there was a slight preponderance 
of patients with performance status of 1 (56%) compared 
with a performance status of zero (44%). At the time of 
analysis (April 28, 2014), the estimated median follow-up 
in all patients using censored deaths method was 
12·2 months (IQR 7·3–18.5); 116 (94%) patients had 
experienced disease progression and 100 (81%) patients 
had died.
Table 2 summarises the incidence of adverse events by 
grade 1–2 and grade 3–4. We noted no signiﬁ cant diﬀ erence 
between treatment groups with respect to grade 3–4 
haematological toxic eﬀ ects, although patients receiving 
cediranib had more frequent grade 3–4 decreased platelet 
counts (table 2). We recorded a signiﬁ cantly higher 
incidence of grade 3–4 hypertension, diarrhoea, and 
fatigue in patients given cediranib than in those given 
placebo (table 2). 88 patient deaths were related to biliary 
tract cancer (43 [86%] in the cediranib group and 45 [90%] 
in the placebo group). In the cediranib group, there was 
one death attributed to treatment (myocardial infarction) 
and one death related to both cancer and treatment (gastric 
haemorrhage). In the placebo group, there were three 
deaths attributed to treatment (one due to peripheral 
ischaemia and stroke; one due to cardiac arrest; and one 
due to pulmonary embolism, superior vena cava 
obstruction, and metastatic gallbladder cancer).
There was no signiﬁ cant diﬀ erence in the median 
duration of treatment (ie, time on treatment) with 
cediranib compared with placebo (4·6 months 
[95% CI 2·8–8·0] with cediranib vs 5·5 months [2·8–7·8] 
with placebo, HR 1·00 [95% CI 0·70–1·44]; p=0·98). 
However, more patients in the cediranib group 
discontinued oral treatment because of toxic eﬀ ects 
(24 in the cediranib group vs 15 in the placebo group; 
ﬁ gure 1). Additionally, 14 (23%) of 62 patients had at least 
one dose reduction and 60 (97%) had at least one 
treatment suspension in a speciﬁ c cycle or month in the 
cediranib group compared with four (7%) of 60 and 
52 (87%) of 60 patients in the placebo group, respectively. 
Allocation of patients to cediranib did not aﬀ ect the 
delivered dose intensity of either cisplatin or gemcitabine 
(data not shown).
At the time of data cutoﬀ , 59 progression-free survival 
events had occurred in the cediranib group as had 57 in 
the placebo group. We noted no signiﬁ cant diﬀ erence in 
median progression-free survival, the primary endpoint of 
the study, between patients given cediranib versus placebo 
(8·0 months [95% CI 6·5–9·3] with cediranib vs 
7·4 months [5·7–8·5] with placebo, HR 0·93 [80% CI 
0·74–1·19, 95% CI 0·65–1·35]; p=0·72). The propor-
tionality assumption of the Cox model used to establish 
the HR was tested and found to hold (p=0·09). 6-month 
progression-free survival was 70·5% (95% CI 57·4–80·3) 
in patients receiving cediranib and 61·3% (48·0–72·1) in 
patients receiving placebo; 12-month progression-free 
survival was 21·8% (95% CI 12·4–32·9) in the cediranib 
group and 16·1% (8·3–26·3) in the placebo group 
(ﬁ gure 2A). Stratiﬁ ed analyses based on sex, age, ECOG 
performance status, primary tumour site, disease status, 
histological grade, previous treatment, and CA19-9 did not 
identify any outliers (appendix).
Most patients (113 [91%]; 59 in the cediranib group and 
54 in the placebo group) had measurable disease at 
baseline. Radiological assessment by Response Evaluation 
Criteria In Solid Tumours (RECIST [version 1.1]) showed a 
greater number of responses in the cediranib group 
compared with the placebo group (26 [44%], including two 
Figure 2: Kaplan-Meier curves for progression-free survival (A), and overall survival (B) by treatment
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[3%] complete responses and 24 [41%] partial responses in 
the cediranib group vs ten [19%] in the placebo group, all 
of which were partial responses; p=0·0036). Stable disease 
was noted in 20 (34%) patients in the cediranib group and 
25 (46%) in the placebo group. As a result, disease control 
was achieved by 46 (78%) patients in the cediranib group 
and by 35 (65%) in the placebo group (p=0·12). The 
median duration of response was 5·1 months (range 
2·2–24) in the cediranib group (26 events in 26 patients) 
and 5·8 months (0·5–22·4) in the placebo group (seven 
events in ten patients). Six (10%) patients in the cediranib 
group and 15 (28%) in the placebo group had progressive 
disease (including symptomatic progressions [ie, not 
objectively obsessed] in three in the cediranib group and 
four in the placebo group). Seven (12%) patients in the 
cediranib group and four (7%) in the placebo group had 
an unknown best overall response.
At data cutoﬀ , 50 (81%) patients in the cediranib group 
and 50 (81%) in the placebo group had died. Median overall 
survival was 14·1 months (95% CI 10·2–16·4) in patients 
given cediranib and 11·9 months (9·2–14·3) in patients 
given placebo (HR 0·86, 95% CI 0·58–1·27; p=0·44). 
6-month overall survival was 85·3% (95% CI 73·6–92·1) in 
the cediranib group and 79·0% (66·6–87·2) in the placebo 
group; at 12 months, 58·1% (95% CI 44·5–69·4) of patients 
receiving cediranib were alive compared with 48·4% 
(35·5–60·1) of patients in the placebo group (ﬁ gure 2B). 
We recorded no diﬀ erence in median overall survival post-
progression on ﬁ rst-line treatment received in this study 
(cediranib 4·5 months [95% CI 2·8–6·4], placebo 
4·3 months [3·3–6·1], HR 0·9 [0·59–1·37]; p=0·62).
Baseline CA19-9 was raised in 71 (68%) of 105 patients; 
an additional 23 (22%) of patients with normal CA19-9 
concentrations had an increased baseline CEA or CA125; 
and 11 (10%) patients had normal levels of all three 
tumour markers (appendix). Cox models for the 
association between baseline tumour markers and 
overall survival (treatment-adjusted HRs) showed that 
increased baseline CA19-9 concentration was associated 
with an increased risk of death (table 3). This was also the 
case with raised CEA and CA125 (table 3). Circulating 
N Overall survival (adjusted for 
treatment only)
Overall survival (adjusted for 
treatment and baseline 
characteristics*)
PFS (adjusted for treatment only)
Deaths HR (95% CI) p value HR (95% CI) p value PFS events HR (95% CI) p value
CEA (μg/L)/10 123 99 1·03 (1·01–1·04) <0·001 1·03 (1·02–1·05) <0·001 115 1·03 (1·01–1·04) 0·001
CA19-9 (IU/mL)/10 000 118 97 1·03 (1·01–1·05) 0·02 1·03 (1·01–1·05) 0·03 110 1·24 (1·04–1·50) 0·02
CA125 (IU/mL)/100 110 88 1·05 (1·01–1·10) 0·03 1·08 (1·03–1·13) 0·001 103 1·08 (1·03–1·13) 0·001
Total CK18 (M65; U/L)/100 119 97 1·03 (1·00–1·05) 0·03 1·04 (1·01–1·06) 0·005 112 1·02 (1·00–1·04) 0·06
CTC count (cells per 7·5 mL) 95 76 1·05 (1·02–1·09) 0·001 1·06 (1·02–1·11) 0·002 89 1·04 (1·01–1·07) 0·01
VEGFR2 (pg/mL)/1000 117 96 1·07 (0·99–1·16) 0·09 1·10 (1·01–1·20) 0·02 110 1·04 (0·96–1·12) 0·34
PFS=progression-free survival. HR=hazard ratio. CTC=circulating tumour cell. The /XX shows the per unit increase; for example, for CEA for every 10 μg/L increase, the 
hazard increases by 3% (HR 1·03). *Baseline characteristics: age, sex, Eastern Cooperative Oncology Group, primary site, stage, previous treatment.
Table 3: Associations between baseline biomarkers and progression-free survival and overall survival
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Figure 3: Kaplan-Meier curves for overall survival, by number of circulating 
tumour cells in 7·5 mL whole blood, collected before treatment
Figure 4: Kaplan-Meier curves for overall survival, by number of circulating VEGFR2 in the plasma, before 
treatment
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total CK18 concentrations were also prognostic, with 
raised baseline concentrations associated with a shorter 
overall survival (table 3).
Blood samples for circulating tumour cell enumeration 
were available from 95 patients before treatment; 51 (54%) 
of 95 patients had a circulating tumour cell count of no 
cells per 7·5 mL blood, 21 (22%) had a count of one cell 
per 7·5 mL blood, and 23 (24%) had a count of two cells or 
higher per 7·5 mL blood, with a median of 0 per 7·5 mL 
blood and mean of 2 per 7·5 mL blood (range 0–44 per 
7·5 mL blood). We noted an association between the 
presence of circulating tumour cells (based on the 
CellSearch criteria) and increased risk of death (HR 1·05, 
95% CI 1·02–1·09); p=0·001; table 3). This same pattern 
was shown when the circulating tumour cell variable was 
divided into tertiles (1 vs 0, HR 3·25 [95% CI 1·81–5·83]; 
≥2 vs 0, HR 3·00 [1·73–5·22], p<0·0001; ﬁ gure 3). Patients 
with no circulating tumour cells in their blood sample had 
the best overall survival (median 18·1 months [95% CI 
12·1–24·9]); the presence of one (median 10·3 months 
[95% CI 4·7–14·4]) or two or more circulating tumour 
cells (median 8·7 months [95% CI 7·1–12·6]) was strongly 
associated with a worse overall survival.
Most of the circulating angiogenesis-related biomarkers 
(VEGFA, VEGFC, VEGFR1, Ang1, Ang2, FGFb, HGF, 
PDGFbb, KGF, PlGF, Tie2, and SDF1b) and the inﬂ am-
matory biomarkers (interleukin 6 and inter leukin 8) did 
not show prognostic signiﬁ cance for overall survival 
(data not shown). However, when adjusted for treatment 
and baseline characteristics, we noted that raised 
concentrations of baseline VEGFR2 were associated with 
an increased risk of death (table 3). This same pattern 
could be seen when we assessed VEGFR2 by tertiles 
(ﬁ gure 4).
We recorded an interaction between baseline PDGFbb 
concentrations and treatment with cediranib for overall 
survival; with the median as the cutoﬀ , we noted that 
patients with concentrations below the median did not 
beneﬁ t from cediranib (ﬁ gure 5A) whereas patients with 
PDGFbb concentrations higher than the median derived 
beneﬁ t from cediranib in terms of overall survival 
(pinteraction=0·002; ﬁ gure 5B and appendix). With respect to 
progression-free survival, our ﬁ ndings suggest that the 
risk of having a progression-free survival event was 
reduced in the cediranib group compared with placebo at 
higher baseline levels of PDGFbb, interleukin 6, 
interleukin 8, PlGF, VEGFA, and Ang1 (appendix).
Discussion
In this multicentre, double-blind placebo-controlled trial 
the addition of cediranib to ﬁ rst-line cisplatin and 
gemcitabine chemotherapy did not improve the pro-
gression-free survival of patients with advanced biliary 
tract cancer; thus, cisplatin and gemcitabine remains a 
standard treatment for these patients.
Based on preclinical and clinical data supporting a 
VEGF-targeted approach, several investigators have 
pursued this approach. Earlier studies have provided 
only limited information, largely because of their single-
group phase 2 design. Sorafenib (an oral multi-tyrosine 
kinase inhibitor) was deemed to have low activity as 
monotherapy, albeit in a mainly second-line setting;20 
bevacizumab (a monoclonal antibody against VEGF) 
with erlotinib (an oral EGFR inhibitor) was feasible in 
the ﬁ rst-line setting although, with a median overall 
survival of 9·9 months, does not seem better than 
upfront chemotherapy.21 In another study,22 bevacizumab 
was tolerable in combination with gemcitabine and 
oxaliplatin; however, we could not work out the 
27
31
25
30
21
29
18
24
11
24
6
18
1
14
0
9
0
8
0
2
0
0
Number at risk
Placebo
Cediranib
0 6 12 18 24 30
0
25
50
75
100
O
ve
ra
ll 
su
rv
iv
al
 (%
)
B
31
28
30
24
25
20
20
13
17
9
13
9
11
6
4
4
4
3
2
1
1
1
Number at risk
Placebo
Cediranib
0 6 12 18 24 30
0
25
50
75
100
O
ve
ra
ll 
su
rv
iv
al
 (%
)
A
Time since randomisation (months)
HR 0·36 (95% CI 0·20–0·67), p=0·001
Placebo
Cediranib
HR 1·47 (95% CI 0·83–2·61), p=0·19
Figure 5: Kaplan-Meier curves for overall survival, by concentrations of circulating PDGFbb in the plasma, 
before treatment
Plots show treatment eﬀ ect by low (A) and high concentrations (B) of PDGFbb at baseline (median 162 pg/mL 
PDGFbb is the cutoﬀ  point), which show evidence of interaction between PDGFbb and treatment.
Articles
976 www.thelancet.com/oncology   Vol 16   August 2015
incremental value of the anti-angiogenic in this single-
group study. Most recently (contemporaneous to our 
study), sorafenib has failed to improve progression-free 
survival when added to gemcitabine in a randomised 
phase 2, placebo-controlled study of 102 patients.23
Our approach is the ﬁ rst to build on the cisplatin and 
gemcitabine chemotherapy regimen, now established as 
a reference regimen; we assessed the eﬀ ect of adding 
cediranib, a pan-VEGF receptor tyrosine kinase inhibitor 
with activity against PDGF receptors and c-KIT in a 
placebo-controlled manner. The study did not meet its 
primary endpoint (to detect a progression-free survival 
HR of 0·64). Despite this shortcoming, some eﬃ  cacy 
ﬁ ndings warrant additional attention; namely signi-
ﬁ cantly greater number of overall responses and 
proportion of patients who achieved disease control in 
those receiving cediranib, mainly at the ﬁ rst (3 month) 
reassessment scan. Response is notoriously diﬃ  cult to 
assess in patients with biliary tract cancer, although the 
risk of bias this could introduce was mitigated by the use 
of a placebo control in this study. Irrespective, patients 
remained on cediranib for a median of 4·6 months, 
stopping earlier than the median progression-free 
survival (8·0 months), mainly because of toxic eﬀ ects; 
moreover, the proportion of patients stopping treatment 
because of toxic eﬀ ects was higher in the cediranib group 
than the placebo group. An examination of the 
progression-free survival Kaplan-Meier curves suggests a 
separation in the period during which cediranib was 
tolerated, which rapidly converged after the median 
cessation point of cediranib. Consistent with this ﬁ nding 
is the numerically greater number of responses in the 
cediranib group. These data suggest that cediranib is 
eﬀ ective during the period of treatment but toxic eﬀ ects 
leading to cessation prevent longer-term beneﬁ t; we 
postulate that a better-tolerated anti-VEGF treatment 
might potentially result in overall beneﬁ t in combination 
with cisplatin and gemcitabine.
We did not note any unexpected safety signals; the 
addition of cediranib to cisplatin and gemcitabine did 
result in a signiﬁ cantly greater incidence of grade 3–4 
toxic eﬀ ects, which were mainly expected oﬀ -target toxic 
eﬀ ects for VEGF inhibitors (namely hypertension and 
diarrhoea). There were three deaths attributed to 
treatment in each group, with no clear additional eﬀ ect 
from cediranib. However, these toxic eﬀ ects were clearly 
signiﬁ cant in this study and need to be considered in any 
future angiogenesis-targeting studies.
The eﬀ ect on the quality of life of patients is important 
in the event that the study had shown beneﬁ t from the 
addition of cediranib as part of the assessment of the 
relative merits of a potentially new agent. However, 
because there was no improvement in progression-free 
survival, quality-of-life ﬁ ndings from this study will be 
reported separately, most likely in a pooled analysis 
with that of other studies of advanced biliary tract 
cancer.
We assessed surrogates of disease volume and biology 
(other than radiological extent) including assessment of 
the tumour markers CA19-9, CEA, and CA125 and total 
CK18. The role of CA19-9 as a marker of volume of 
disease, prognostic factor, and measure of response to 
treatment is well documented.24 However, because this is 
linked to the Lewis blood-group antigen, not all patients 
express this (32% were CA19-9-negative in our series). 
We have been able to show that in roughly one in ﬁ ve 
cases (22%), CEA or CA125 might be used as an 
alternative and that each of these also has prognostic 
value, with increased baseline levels independently 
correlating with an adverse overall survival.
Cancers of epithelial origin contain large intracellular 
pools of cytokeratins; during necrotic or apoptotic cell 
death CK18 and other cytokeratins are released into the 
blood in either their intact or their caspase-cleaved forms 
where they remain stable in the circulation.25 CK18 is 
proposed as a surrogate biomarker of drug-induced 
epithelial cell death26 and thus might not only represent 
epithelial tumour cell death but may also reﬂ ect toxic 
eﬀ ects in epithelial host tissues. We have shown here for 
the ﬁ rst time, to the best of our knowledge, that increased 
baseline CK18 levels are adversely prognostic in biliary 
tract cancer, consistent with our previous ﬁ ndings in 
colorectal cancer.27
The presence of circulating tumour cells is prognostic in 
a number of cancer types including prostate, breast, and 
colorectal cancers where CellSearch enumeration of 
circulating tumour cells is approved by the US Food and 
Drug Administration for prognosis and monitoring. We 
have shown that circulating tumour cells number by 
CellSearch is also prognostic in lung cancer,28,29 pancreatic 
cancer,30 hepatocellular carcinoma,31 and melanoma.32 
Our study is, to the best of our knowledge, the ﬁ rst to 
show the presence of circulating tumour cells in patients 
with biliary tract cancer and, moreover, that the presence 
of one or more circulating tumour cells per 7·5 mL of 
blood is associated with an adverse prognosis. This 
ﬁ nding (subject to further validation) could not only 
inform future study design, but might also serve as a 
platform for longitudinal surveillance of disease behaviour 
both in terms of circulating tumour cell enumeration and 
detailed molecular analysis of individual cells.
As previously discussed, VEGF and its receptors are 
overexpressed in patients with biliary tract cancer; 
correlating with the presence of metastases and an 
adverse prognosis. Baseline VEGFR2 levels are associated 
with progression-free survival (but not overall survival) in 
cediranib studies in hepatocellular carcinoma,33 although 
were not prognostic (for progression-free survival or 
overall survival) in colorectal cancer.34 Assessment of a 
panel of angiogenesis-associated biomarkers in our study 
identiﬁ ed VEGFR2 as a novel adverse prognostic marker 
for overall survival in this disease group; however, despite 
this being a major target of cediranib with pharma-
codynamic properties reported in the phase 1 study,35 
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baseline concentrations were not associated with a 
treatment eﬀ ect (ie, were not predictive).
PDGF, a mitogen chemotactic factor promoting wound 
healing, neoplastic transformation, and tumour patho-
genesis, is a dimeric molecule that, when active, exists 
either as a homodimer or a heterodimer of a and b 
chains.36 In-vitro and in-vivo studies have identiﬁ ed that 
myoﬁ broblast-derived PDGFbb is potentially cyto-
protective to cholangiocarcinoma cells by inhibition of the 
TRAIL (death ligand) cytotoxicity.37 In our study, increased 
baseline levels of PDGFbb, one of the targets of cediranib, 
was associated with a beneﬁ t from cediranib consistent 
with a potential role as a predictive biomarker; this ﬁ nding 
would need to be validated in an independent cohort.
In summary, the addition of cediranib to cisplatin and 
gemcitabine chemotherapy did not improve progression-
free survival. However, VEGF inhibition might still be an 
avenue worth pursuing, perhaps with an agent that has a 
toxic eﬀ ect proﬁ le that allows more sustained dosing with 
cisplatin and gemcitabine than cediranib. Integration into 
future trial designs of the circulating biomarkers identiﬁ ed 
in our study (VEGFR2, total CK18 in addition to the 
tumour markers CA125, CEA, and CA19-9) will depend on 
validation of their utility. Finally, our identiﬁ cation of 
circulating tumour cells in patients with biliary tract 
cancers will allow risk stratiﬁ cation via circulating tumour 
cell enumeration and, coupled with our recently developed 
protocols for circulating tumour cell isolation and single 
cell genomic and transcriptomic proﬁ ling,38,39 could open 
up new avenues for minimally invasive monitoring and 
delivery of precision medicine for these patients.
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